Natera stock trades near 52-week high as guidance and regulatory wins support growth
Published on 09/04/2026 at 12:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Natera stock (ISIN US6323071042) is trading close to its 52-week high after the genetic testing specialist reported robust second-quarter 2026 growth, raised its full-year revenue guidance and secured an important reimbursement decision that supports its Prospera transplant tests, according to recent market and media data as of September 4, 2026.
Strong Q2 figures and higher 2026 guidance
According to a recent analysis of Natera’s latest results, the company generated second-quarter 2026 revenue of about USD 753 million, clearly ahead of a Wall Street forecast of roughly USD 661.26 million, reflecting accelerated growth across its main business segments.
The same sources report that Natera’s management has raised its full-year 2026 revenue guidance to a range of USD 2.85 billion to USD 2.91 billion, underlining confidence in the demand outlook and signaling that current test volumes and margins are tracking above earlier expectations.
Operationally, Natera processed more than 1,040,000 tests in the second quarter of 2026, representing an increase of 22 percent compared with the prior-year quarter, while revenue climbed by 38 percent year on year to USD 753 million, a combination that highlights both volume expansion and improved monetization per test.
Regulatory tailwind from MolDx coverage decision
A detailed report from a European technology and health news outlet describes how a new publication in the journal Blood Neoplasia strengthens the clinical case for Natera’s Signatera assay in lymphoma, citing a positive predictive value of 100 percent for therapy response in the studied setting.
In parallel, the same report notes that the MolDx Local Coverage Determination L40060 has now come into effect, expanding reimbursement for Natera’s Prospera transplant tests and specifying that for kidney transplants six tests are covered in the first year and four tests per year in subsequent years.
For heart and lung transplants, test quotas are also increased under the updated MolDx framework, giving Natera a clearer pathway to recurring reimbursed testing volumes in solid-organ transplant monitoring and underpinning the company’s decision to invest in AI-supported ctDNA surveillance partnerships.
Insider sales against a backdrop of strong share performance
Recent regulatory filings and financial-press summaries show that Natera’s president of clinical diagnostics, Solomon Moshkevich, sold a total of 18,160 Natera shares over two days, September 1 and September 2, 2026, at prices between USD 319.7582 and USD 326.894 per share, for proceeds of about USD 5.92 million.
On September 1, 2026, these insider transactions included blocks of 1,000, 1,400 and 600 shares at ranges between roughly USD 319.2850 and USD 322.11, while on September 2, 2026, an additional 15,160 shares were sold at USD 326.894 per share, illustrating that the disposals occurred while the stock was already trading near the upper end of its recent range.
Separate filings show that Natera’s chief executive officer, Steven Leonard Chapman, sold 1,698 shares of Natera common stock on September 1, 2026 at a price of USD 320.99 per share, for a transaction value of approximately USD 545,041, leaving him with a direct holding of 98,199 shares after the sale.
Share price near 52-week highs and year-to-date gains
Market data compiled by US stock portals indicate that Natera stock closed at USD 327.67 on September 3, 2026 on the Nasdaq, up USD 2.50 on the day, with extended-hours trading quotes around USD 329.22, placing the share price close to a reported 52-week high of USD 343.18.
The same data set highlights that Natera shares have delivered a return of about 97 percent over the past twelve months, while separate coverage points to a year-to-date gain of approximately 42 percent, suggesting that investors have been willing to reward the company’s rapid revenue growth and improved margin trajectory.
For investors watching technical levels, European market commentary cites a recent euro-denominated price for Natera of EUR 279.80, near a local 52-week high of EUR 296.00 reached on August 27, 2026, giving a tangible sense of how close the stock is trading to its recent peaks on that venue.
Analyst support from US banks
Analyst coverage has also turned more constructive in recent weeks, with one report noting that Citigroup raised its price target for Natera to USD 365.00 from USD 315.00 on August 13, 2026 while maintaining a Buy rating, pointing to the company’s strong test volume growth and regulatory catalysts.
Another US broker, Piper Sandler, is cited as increasing its price target to USD 363.50 on August 12, 2026 with an Overweight stance, while research updates from firms such as Stephens and Guggenheim mention revised targets of USD 350.00 and USD 360.00, respectively, underscoring a broad-based analyst expectation of further upside potential.
For retail investors, the combination of raised price targets, positive earnings surprises and favorable reimbursement decisions provides a concrete framework to understand why Natera stock is trading at elevated valuation levels compared with many other diagnostics and genomics peers.
More background on Natera stock
Readers who want to explore further coverage of Natera stock and its recent earnings and regulatory developments can find additional articles and filings via our topic page and the company’s own investor information.
Signatera test supports oncology segment
Signatera, Natera’s personalized circulating tumor DNA assay, plays a central role in the company’s oncology business by enabling minimal residual disease detection and treatment monitoring, and the recent Blood Neoplasia publication for lymphoma adds further clinical evidence in a cancer indication where reliable biomarkers can be difficult to establish.
By demonstrating a positive predictive value of 100 percent for therapy response in the reported lymphoma study, Signatera’s clinical performance strengthens Natera’s case when negotiating reimbursement and guideline inclusion, and may help drive adoption among hematologists and oncologists seeking more precise tools for tracking disease dynamics.
Industry observers note that Natera continues to expand AI-supported ctDNA monitoring through partnerships, integrating machine learning into its analytical pipelines to improve signal detection and interpretation across diverse tumor types and patient populations.
Prospera transplant tests benefit from expanded coverage
In transplant medicine, Natera’s Prospera tests are designed to monitor organ health and rejection risk using cfDNA analysis, and the MolDx L40060 coverage decision is particularly relevant for payers and clinicians because it codifies how many reimbursed tests can be ordered for kidney, heart and lung transplant recipients.
For kidney transplants, the rule of six tests in the first year and four tests in each subsequent year provides a structured schedule that transplant centers can incorporate into standard-of-care protocols, creating predictable recurring revenue streams for Natera as long as clinical performance remains supportive.
Heart and lung transplant programs similarly benefit from increased reimbursement for Prospera testing, according to the same coverage description, which should help Natera deepen its presence in this niche yet high-value segment of diagnostic medicine over time.
Stock performance and investor perspective
From an investor perspective, Natera’s combination of strong quarterly revenue growth, raised guidance for full-year 2026 and expanding reimbursement for key products helps explain why the stock is trading close to its 52-week high of USD 343.18 and has delivered about 97 percent over the past twelve months.
At the same time, the recent insider sales by senior executives, totaling more than USD 6.46 million across the CEO and the president of clinical diagnostics at prices between USD 319.7582 and USD 326.894 per share, provide a reminder that some management shareholders are realizing gains after the rally, a factor that some investors may weigh alongside the positive fundamental story.
As of the September 3, 2026 close, Natera’s market capitalization based on the USD 327.67 share price stands in the multi-billion-dollar range in US dollars, positioning the company among the larger players in the global genetic testing and diagnostics space.
Stock price snapshot
On Nasdaq, Natera stock closed at USD 327.67 on September 3, 2026, with an extended-hours indication of USD 329.22 as of early September 4, 2026, placing the shares within roughly 4.5 percent of the reported 52-week high of USD 343.18.
For investors in German-speaking markets, commentary citing a price of EUR 279.80 for Natera on a European venue on August 27, 2026, near a 52-week high of EUR 296.00, underlines the broad international interest in the stock and its sensitivity to clinical and reimbursement news flow.
Natera stock at a glance
- Company: Natera, Inc.
- ISIN: US6323071042
- Ticker: NTRA
- Trading venue: Nasdaq
- Price (as of September 3, 2026, 16:00): 327.67 USD
- Market capitalization: multi-billion USD (as of September 3, 2026)
- Sector / Industry: Health Care / Diagnostics
- Index membership: not part of a major blue-chip index
